Lugui Qiu

2.1k total citations
125 papers, 1.0k citations indexed

About

Lugui Qiu is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Lugui Qiu has authored 125 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Hematology, 48 papers in Oncology and 42 papers in Genetics. Recurrent topics in Lugui Qiu's work include Multiple Myeloma Research and Treatments (42 papers), Chronic Lymphocytic Leukemia Research (36 papers) and Lymphoma Diagnosis and Treatment (32 papers). Lugui Qiu is often cited by papers focused on Multiple Myeloma Research and Treatments (42 papers), Chronic Lymphocytic Leukemia Research (36 papers) and Lymphoma Diagnosis and Treatment (32 papers). Lugui Qiu collaborates with scholars based in China, United States and United Kingdom. Lugui Qiu's co-authors include Manujendra N. Saha, Gang An, Kenneth C. Anderson, Yu‐Tzu Tai, Li Zhang, Hong Chang, Yijun Yang, Nikhil C. Munshi, Kenneth Wen and Xiaoyan Feng and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Lugui Qiu

106 papers receiving 1.0k citations

Peers

Lugui Qiu

HEMAT

ONCOL

GENET

IMMUN

Francesca Arruga Italy

Francesco Paolo Tambaro United States

Cristina Rabascio Italy

Linda Wellik United States

Dariusz Wołowiec Poland

Chirag Acharya United States

Fotis Asimakopoulos United States

Yuri Kamitsuji Japan

Nadja Zaborsky Austria

Lynn Quek United Kingdom

Francesca Arruga Italy

Lugui Qiu

502 ×1.0

394 ×1.0

HEMAT

312 ×1.0

ONCOL

550 ×2.3

GENET

332 ×1.5

IMMUN

Citations per year, relative to Lugui Qiu Lugui Qiu (= 1×) peers Francesca Arruga

Countries citing papers authored by Lugui Qiu

Since Specialization

Citations

This map shows the geographic impact of Lugui Qiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lugui Qiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lugui Qiu more than expected).

Fields of papers citing papers by Lugui Qiu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lugui Qiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lugui Qiu. The network helps show where Lugui Qiu may publish in the future.

Co-authorship network of co-authors of Lugui Qiu

This figure shows the co-authorship network connecting the top 25 collaborators of Lugui Qiu. A scholar is included among the top collaborators of Lugui Qiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lugui Qiu. Lugui Qiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Yi, Yuting Yan, Dandan Shan, et al.. (2025). Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma. Cancer Biology and Medicine. 22(2). 177–189. 1 indexed citations

An, Gang, Yafei Wang, Hui Guo, et al.. (2025). QLS4131, a next-generation GPRC5D×BCMA×CD3 trispecific T-cell engager, in patients with relapsed/refractory multiple myeloma (RRMM): Initial results of a first-in-human Phase Ⅰa study. Blood. 146(Supplement 1). 5831–5831.

Li, Chunrui, Dehui Zou, He Huang, et al.. (2024). Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study. Blood. 144(Supplement 1). 4761–4761. 2 indexed citations

Sui, Weiwei, Tengteng Yu, Yuting Yan, et al.. (2024). CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities. Blood. 144(Supplement 1). 3386–3386.

Sun, Mingyuan, Hongmei Jing, Fei Dong, et al.. (2024). Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma. Scientific Reports. 14(1). 27550–27550.

Xu, Yan, Wensi Li, Gang An, et al.. (2023). Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy. Blood. 142(Supplement 1). 6864–6864. 1 indexed citations

Liu, Wei, Haiyan Yang, Zhen Cai, et al.. (2023). A Phase Ib Study of Linperlisib Monotherapy in Patients with Relapsed or Refractory B-Cell Malignancies. Blood. 142(Supplement 1). 1722–1722. 1 indexed citations

Bai, Yang, Zhen Yu, Shuhua Yi, et al.. (2020). Raman spectroscopy-based biomarker screening by studying the fingerprint characteristics of chronic lymphocytic leukemia and diffuse large B-cell lymphoma. Journal of Pharmaceutical and Biomedical Analysis. 190. 113514–113514. 28 indexed citations

Hillmen, Peter, Jennifer R. Brown, John C. Byrd, et al.. (2019). Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood. 134(Supplement_1). 4307–4307. 2 indexed citations

10.

Wang, Xiaojing, Gang An, Jiying Wang, et al.. (2018). The association of HLA-C alleles with multiple myeloma in Chinese patients. Experimental Hematology and Oncology. 7(1). 19–19. 5 indexed citations

11.

Li, Heng, Shuhua Yi, Wenjie Xiong, et al.. (2017). Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia.. SHILAP Revista de lepidopterología. 130(2). 135–142. 5 indexed citations

12.

Liu, Xin, Erlie Jiang, Yong Huang, et al.. (2017). Which Patients with Ph+ Acute Lymphoblastic Leukemia Should Undergo Autologous Hematopoietic Stem Cell Transplantation in TKI Era?. Blood. 130. 3286–3286. 1 indexed citations

13.

Hao, Mu, Hua Bai, Zhimin Gu, et al.. (2017). The Interaction of NEK2 with USP7 Causes Resistance to Proteasome Inhibitor in Multiple Myeloma. Blood. 130. 593–593. 1 indexed citations

14.

Zhu, Jun, Jianyong Li, Jianfeng Zhou, et al.. (2017). BGB-3111, a Highly Specific BTK Inhibitor, Is Well Tolerated and Highly Active in Chinese Patients with Relapsed/Refractory B-Cell Malignancies: Initial Report of a Phase 1 Trial in China. Blood. 130. 5347–5347. 3 indexed citations

15.

Yang, Yijun, Fei Li, Manujendra N. Saha, et al.. (2015). miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma. Clinical Cancer Research. 21(10). 2399–2411. 100 indexed citations

16.

Hao, Mu, Meirong Zang, Yan Xu, et al.. (2015). Serum High Expression of Micorna-214 Is a Novel Predictor for Myeloma Bone Disease and Poor Prognosis. Blood. 126(23). 4186–4186. 2 indexed citations

17.

Lu, Jin, Jae Hoon Lee, Shang‐Yi Huang, et al.. (2015). Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial. Blood. 126(23). 4240–4240. 4 indexed citations

18.

Yi, Shuhua, Rui Cui, Zengjun Li, et al.. (2014). Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenström macroglobulinemia. Chinese Medical Journal. 127(12). 2327–2331. 4 indexed citations

19.

Wang, Yafei, et al.. (2010). Applicability of different clinical staging systems in chronic lymphocytic leukemia for Chinese patients. 19(3). 136–139. 1 indexed citations

20.

Xu, Yan, Hengxing Meng, Changhong Li, et al.. (2010). Umbilical Cord-Derived Mesenchymal Stem Cells Isolated by a Novel Explantation Technique Can Differentiate into Functional Endothelial Cells and Promote Revascularization. Stem Cells and Development. 19(10). 1511–1522. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact